Die hochgeladenen ePoster sind nur für eingeloggte Teilnehmer ersichtlich.
Bitte loggen Sie sich ein, um zu den ePoster zu gelangen.
Beitragstitel | 36-Month Outcomes of Combined Ab Interno Viscocanaloplasty (ABiC) in the Surgical Treatment of Open-Angle Glaucoma |
---|---|
Beitragscode | P09 |
Autor:innen | |
Präsentationsform | ePoster |
Themengebiete |
|
Abstract-Text |
Introduction: Ab interno viscocanaloplasty (ABiC) derives from ab externo viscocanalostomy and involves the catheterization of Schlemm’s canal with a flexible microcatheter through which viscoelastic material is injected to dilate the canal and its surrounding structures on 360°.The aim of this study was to analyze the safety profile and efficacy of ABiC through to 36 months post-operatively. Methods: In this retrospective study carried out at a tertiary ophthalmology centre, all patients who underwent ABiC between January 2016 and January 2017 were retrospectively enrolled, and their medical records were analysed. Complete success was defined as a 36-month reduction in intraocular pressure (IOP) ≥ 20% from baseline with no concomitant medications. Qualified success criteria were identical, with no more medications than at baseline. When longer follow-up periods were available, mean IOP and medications were reported at the last visit. Results: In all, 30 eyes of 25 patients were analysed, with a mean follow-up time of 42.3 ± 4.6 months. Mean IOP decreased from 25.9 ± 9.2 mmHg preoperatively to 13.8 ± 4.0 mmHg (-46.7%; p < 0.001) at the last visit. Concomitantly, the number of medications dropped from 3.4 ± 0.9 to 1.0 ± 1.2 (-70.6%; p < 0.001). Complete success at 36 months was achieved in 20% of eyes, and qualified success in 53%. Amongst eyes with a baseline MD < -9 dBs, 20% and 100% achieved complete and qualified success, respectively, and 66.7% of eyes that had previously undergone filtering surgery achieved both complete and qualified success, with a mean 3-year IOP of 10.7 ± 3.2 mmHg. A total of 14 eyes (46.7%) were considered surgical failure due to uncontrolled IOP, 8 of which (26.7%) required further filtering surgery. Sixteen adverse events were observed during the follow-up period, with IOP spikes > 30 mmHg during the first post-operative week being the most common complication (36.7%). Conclusions: ABIC achieved a statistically significant reduction in IOP and anti-glaucoma medications through 3 years of follow-up, with a favourable safety profile. It may be a valid technique to allow long-term control of IOP in mild-to-severe open-angle glaucoma, including after failed filtering surgery. |